Revenue beat consensus and guidance midpoint raised, but the underlying trend is declining COVID-19 vaccine revenue as the company transitions to oncology. Key catalysts to watch: the first interim analysis of the gotistobart Phase 3 PRESERVE-003 trial expected in 2026, and the OS readout from the BNT113 AHEAD-MERIT trial. The trastuzumab pamirtecan BLA submission timeline remains under discussion.
Drugs in focus
BNTX drug pipeline →gotistobart
● Neutral Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
- Next catalyst
- None dated
What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.
Price Chart
Executive Summary
BioNTech reported Q3 2026 revenue of 1,289.2 million (down 15% YoY from 1,518.9 million) and IFRS net profit of 184.5 million vs a loss of 28.7 million a year ago. The company raised the midpoint of its full-year 2026 revenue guidance to 1.7-1.9 billion from 1.6-1.9 billion, citing Q3 performance. Revenue also exceeded the 1.04 billion consensus. However, year-to-date revenues declined 23% and the company remains in an IFRS net loss position year-to-date, reflecting declining COVID-19 vaccine demand offset by growing pipeline investments.
Key Financial Metrics
Key Facts
- Q3 2026 IFRS revenue 1,289.2 million vs 1,518.9 million in Q3 2025 (down 15.1% YoY)
- Q3 2026 IFRS net profit 184.5 million vs net loss of 28.7 million in Q3 2025
- Q3 2026 adjusted diluted EPS 1.76 vs adjusted diluted EPS 3.11 in Q3 2025
- Raised full-year 2026 revenue guidance midpoint to 1.7-1.9 billion from 1.6-1.9 billion
- Cash, cash equivalents and security investments of 16.2 billion as of September 30, 2026
- Share repurchase program: 5,037,452 ADSs repurchased for 463.3 million through September 30, 2026
- BNT113 Phase 2/3 trial in HNSCC did not meet PFS endpoint; trial continues for OS
- Trastuzumab pamirtecan Phase 3 DYNASTY-Breast02 met PFS with modest improvement; higher ILD rate observed
- Early termination initiated in Phase 2 trial of autogene cevumeran in adjuvant CRC
Financial Impact
Q3 revenue 1,289.2 million vs consensus 1.04 billion; adjusted diluted EPS 1.76 vs consensus 0.76 per ADS
Risk Factors
- Declining COVID-19 vaccine revenue as pandemic demand normalizes
- BNT113 failed PFS endpoint; OS readout needed to determine trial outcome
- Trastuzumab pamirtecan showed modest PFS benefit with higher ILD rate, potentially limiting commercial opportunity
- Year-to-date IFRS net loss of 1,168.2 million driven by high R&D spending and restructuring costs
- Autogene cevumeran Phase 2 CRC trial terminated early
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000080 |
| Document: a992bntx3q2026presentati.htm | 0001776985-26-000080 |
| Document: form6-kq32026earningsprear.htm | 0001776985-26-000080 |
| Document: 0001776985-26-000080-index-headers.html | 0001776985-26-000080 |
| Document: 0001776985-26-000080-index.html | 0001776985-26-000080 |
| Document: 0001776985-26-000080.txt | 0001776985-26-000080 |
| Earnings Context (Synthetic; results releases only) | 0001776985-26-000080 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 Viewing No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers